Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide + Chemotherapy in p53-mutated Pediatric Cancer
NCT06088030Phase 2Recruiting
- Start
- Dec 2023
- Primary completion
- Dec 2031
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in pediatric cancer, Li-Fraumeni syndrome (LFS). Started Dec 2023; status: recruiting.
02
Drugs
arsenic trioxide
03
Conditions
pediatric cancerLi-Fraumeni syndrome (LFS)
Beyond the preview
Go deeper on NCT06088030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088030.